<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02876601</url>
  </required_header>
  <id_info>
    <org_study_id>LPS_DF Version 1.2</org_study_id>
    <nct_id>NCT02876601</nct_id>
  </id_info>
  <brief_title>Defibrotide in the Human Endotoxemia Model --‐ an Exploratory Trial Investigating the Effects and the Mechanisms of Defibrotide</brief_title>
  <acronym>LPS_DF</acronym>
  <official_title>Defibrotide in the Human Endotoxemia Model -- an Exploratory Trial Investigating the Effects and the Mechanisms of Defibrotide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bernd Jilma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Defibrotide is an anti-inflammatory and anti-coagulatory agent approved for treatment of
      veno-occlusive disease. Although it has been in clinical use for almost 30 years, the exact
      mechanism of action has never been fully elucidated. Thus, the effects of defibrotide will be
      investigated in the human endotoxemia model in order to gather further information on its
      actions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Defibrotide (DF) is a highly complex polydisperse mixture of single-stranded phosphodiester
      oligodeoxyribonucleotides derived from the controlled depolymerization of porcine intestinal
      mucosal DNA. The entire mode of action remains unknown. Its actions may be summarized to
      pro-fibrinolytic, anti-inflammatory and anti-coagulatory actions. To better define the
      mechanisms of Defibrotide the effects of the substance will be investigated in the
      well-established endotoxemia model. Sixteen healthy volunteers will be randomized to receive
      LPS±defibrotide/placebo and four subjects will be randomized to receive Placebo±
      defibrotide/placebo in a single center, randomized, double blind, placebo controlled, two-way
      crossover trial. Immediately after a 2h infusion of 6,25mg/kg bodyweight defibrotide or
      placebo a LPS bolus of 2ng/kg bodyweight will be infused. Analyses will be performed by blood
      sampling at pre-defined time-points.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2017</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in prothrombin fragments f1+2</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>by elisa, the changes will be compared between the placebo and the verum phase within each subject</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in coagulation specific biomarkers</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Thrombin-Antithrombin Complexes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Fibrinolytic biomarkers</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>by elisa, D-Dimer, Plasmin-Antiplasmin Complexes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory biomarkers</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>C-reactive Protein levels, Fibrinogen, TNF-alpha</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in microparticle associated tissue factor activity</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>by elisa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Biomarkers of endothelial activation</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>by elisa, von-willebrand-factor, E-selectin,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Biomarkers of endothelial activation</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Circulatin Endothelial cells by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differential blood counts</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>by flow cytometry, incl. platelet counts, absolute and relative counts of leucocytes, erythrocytes, and leucocyte subpopulations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure mmHg</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>safety parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Temperature degrees centigrade</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>safety parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen Saturation in percent</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>safety parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate in beats per minute</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>safety parameters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Endotoxemia</condition>
  <arm_group>
    <arm_group_label>LPS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2ng/kg lipopolysaccharide period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (0.9% sodium chloride) period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Defibrotide</intervention_name>
    <description>6.25mg/kg bodyweight over 2h infusion</description>
    <arm_group_label>LPS</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (0.9% sodium chloride)</intervention_name>
    <description>(0.9% sodium chloride) infusion over 2h infusion</description>
    <arm_group_label>LPS</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipopolysaccharide</intervention_name>
    <description>bolus infusion of 2ng/kg bodyweight lps</description>
    <arm_group_label>LPS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 years of age

          -  &lt;90kg body weight

          -  Normal findings in medical history and physical examination unless the investigator
             considers the abnormality to be clinically irrelevant

          -  Normal laboratory values unless the investigator considers abnormalities to be
             clinically irrelevant

          -  Ability to understand the purpose and nature of the study, as well as the associated
             risks

        Exclusion Criteria:

          -  Intake of any drugs that may interfere with the trial's endpoints or drugs (i.e.
             platelet inhibitors, anticoagulants, etc.)

          -  Positive results of HIV or hepatitis virology

          -  Acute illness with systemic inflammatory reactions

          -  Known allergies, hypersensitivities or intolerances to any of the used substances

          -  Acute or recent bleeding episodes, increased risk of bleeding at the discretion of the
             investigator

          -  Participation in an LPS trial within 6 weeks of the first study day

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernd Jilma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bernd Jilma, MD</last_name>
    <phone>+43 1 40400</phone>
    <phone_ext>29810</phone_ext>
    <email>bernd.jilma@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Schoergenhofer, MD</last_name>
    <phone>+43 1 40400</phone>
    <phone_ext>29810</phone_ext>
    <email>christian.schoergenhofer@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Zeitlinger, MD</last_name>
      <phone>+43 1 40400</phone>
      <phone_ext>29810</phone_ext>
      <email>markus.zeitlinger@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Bernd Jilma, MD</last_name>
      <phone>+43 1 40400</phone>
      <phone_ext>29810</phone_ext>
      <email>bernd.jilma@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Bernd Jilma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Schoergenhofer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johann Bartko, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philipp Wohlfarth, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Werner Rabitsch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georg Hopfinger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2016</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Bernd Jilma</investigator_full_name>
    <investigator_title>Ao.Univ.Prof.Dr.med</investigator_title>
  </responsible_party>
  <keyword>Coagulation</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Defibrotide</keyword>
  <keyword>Fibrinolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endotoxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Defibrotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be published in a peer-reviewed medical journal, individual data will not be presented or published, but may be made available by direct request to the PI (data may be made available in an anonymized fashion)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

